BR112014029856A2 - formulação farmacêutica, métodos para determinar se células t reconhecem um polipeptídeo, para tratar um indivíduo contra alergia a alternaria e/ou cladosporium ou de prevenir em um indivíduo alergia a alternaria e/ou cladosporium, e para preparar uma formulação farmacêutica da invenção, uso de pelo menos três polipeptídeos ou sais, e, polipeptídeo ou sal - Google Patents

formulação farmacêutica, métodos para determinar se células t reconhecem um polipeptídeo, para tratar um indivíduo contra alergia a alternaria e/ou cladosporium ou de prevenir em um indivíduo alergia a alternaria e/ou cladosporium, e para preparar uma formulação farmacêutica da invenção, uso de pelo menos três polipeptídeos ou sais, e, polipeptídeo ou sal

Info

Publication number
BR112014029856A2
BR112014029856A2 BR112014029856A BR112014029856A BR112014029856A2 BR 112014029856 A2 BR112014029856 A2 BR 112014029856A2 BR 112014029856 A BR112014029856 A BR 112014029856A BR 112014029856 A BR112014029856 A BR 112014029856A BR 112014029856 A2 BR112014029856 A2 BR 112014029856A2
Authority
BR
Brazil
Prior art keywords
amino acid
polypeptide
acid sequence
salt
sequence
Prior art date
Application number
BR112014029856A
Other languages
English (en)
Portuguese (pt)
Inventor
Larche Mark
Hickey Pascal
Laidler Paul
Peter Hafner Roderick
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46582267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014029856(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of BR112014029856A2 publication Critical patent/BR112014029856A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Ecology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
BR112014029856A 2012-06-01 2013-05-30 formulação farmacêutica, métodos para determinar se células t reconhecem um polipeptídeo, para tratar um indivíduo contra alergia a alternaria e/ou cladosporium ou de prevenir em um indivíduo alergia a alternaria e/ou cladosporium, e para preparar uma formulação farmacêutica da invenção, uso de pelo menos três polipeptídeos ou sais, e, polipeptídeo ou sal BR112014029856A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1209868.7A GB201209868D0 (en) 2012-06-01 2012-06-01 Alternaria peptides
PCT/GB2013/051439 WO2013179043A1 (en) 2012-06-01 2013-05-30 Alternaria peptides

Publications (1)

Publication Number Publication Date
BR112014029856A2 true BR112014029856A2 (pt) 2017-07-25

Family

ID=46582267

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029856A BR112014029856A2 (pt) 2012-06-01 2013-05-30 formulação farmacêutica, métodos para determinar se células t reconhecem um polipeptídeo, para tratar um indivíduo contra alergia a alternaria e/ou cladosporium ou de prevenir em um indivíduo alergia a alternaria e/ou cladosporium, e para preparar uma formulação farmacêutica da invenção, uso de pelo menos três polipeptídeos ou sais, e, polipeptídeo ou sal

Country Status (17)

Country Link
US (1) US20150098969A1 (https=)
EP (1) EP2855515A1 (https=)
JP (1) JP2015520771A (https=)
KR (1) KR20150028788A (https=)
CN (1) CN104507959A (https=)
AU (1) AU2013269326A1 (https=)
BR (1) BR112014029856A2 (https=)
CA (1) CA2875130A1 (https=)
CL (1) CL2014003290A1 (https=)
EA (1) EA201492268A1 (https=)
GB (2) GB201209868D0 (https=)
HK (1) HK1201752A1 (https=)
IL (1) IL235840A0 (https=)
IN (1) IN2014DN10558A (https=)
MX (1) MX2014014461A (https=)
SG (1) SG11201407975TA (https=)
WO (1) WO2013179043A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014195382A1 (en) * 2013-06-05 2014-12-11 Alergenetica Sl T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400723B (de) * 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
JP2007176953A (ja) * 1996-03-10 2007-07-12 Meiji Milk Prod Co Ltd アレルギー疾患に対するペプチド免疫療法剤
JP2003116556A (ja) * 2001-10-09 2003-04-22 Nippon Zenyaku Kogyo Kk アレルギー性皮膚炎治療剤
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
NZ583362A (en) * 2007-08-15 2012-06-29 Circassia Ltd Peptide with reduced dimer formation
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
WO2012038540A2 (en) * 2010-09-24 2012-03-29 Alergenetica Sl Peptides

Also Published As

Publication number Publication date
US20150098969A1 (en) 2015-04-09
AU2013269326A1 (en) 2014-12-18
CN104507959A (zh) 2015-04-08
EA201492268A1 (ru) 2015-05-29
MX2014014461A (es) 2015-02-10
CL2014003290A1 (es) 2015-05-22
IL235840A0 (en) 2015-01-29
KR20150028788A (ko) 2015-03-16
IN2014DN10558A (https=) 2015-08-21
GB201209868D0 (en) 2012-07-18
EP2855515A1 (en) 2015-04-08
JP2015520771A (ja) 2015-07-23
HK1201752A1 (en) 2015-09-11
SG11201407975TA (en) 2015-01-29
WO2013179043A1 (en) 2013-12-05
GB2517871A (en) 2015-03-04
CA2875130A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
PE20080397A1 (es) Proteinas de fusion del receptor de productos finales de glicacion avanzada (ragepor sus sigla en ingles), formulaciones, y metodos de uso de las mismas
TW201613958A (en) MIC-1 fusion proteins and uses thereof
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
MX2012002216A (es) Nueva endolisina obpgplys.
BR112014023374A2 (pt) composições de peptídeos de glp-1 e preparação das mesmas
EA201490393A1 (ru) Соматотропный гормон пролонгированного действия и способы его получения
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
MX2019013628A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
BR112016029582A2 (pt) derivados de exendina-4 como agonistas de receptor de glucagon seletivos
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
AR068302A1 (es) Peptidos para vacunas para canceres que expresan antigenos asociados con tumores
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
EP3939606A3 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
UY38068A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
PH12015502005B1 (en) New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]